logo

English
  • Svenska
  • About Us
    About Us
      • This is Calliditas
      • Vision and Strategy
      • Board of Directors
      • Management Team
      • Our History
      • Corporate Responsibility
        • Expanded Access Policy
      • Careers
  • Science
    Science
      • Our Pipeline
      • Nefecon (ex-US Markets)
      • Setanaxib – NOX Platform
      • Orphan drugs
  • Our Product
  • Governance
    Governance
      • Corporate Governance
      • Corporate Governance Reports
      • Corporate Structure
      • General Meeting
        • Annual general meeting 2022
        • General meetings
      • Nomination Committee
        • Nomination committees
      • Board and Committees
        • Board of Directors
        • Board fees
        • Work of the Board of Directors
        • Committees
      • Management
        • Management team
      • Remuneration
      • Internal Control and Risk Management
      • Auditor
      • Articles of Association
  • Investors
    Investors
      • The Share
        • Trading information
        • Ownership structure
        • Share capital development
        • Dividend policy
        • Analyst coverage
      • Financial Reports and Presentations
      • SEC Filings
      • Press Releases
      • Financial Calendar
      • IR Calendar
      • Subscribe
      • Contacts
      • Investor FAQs
  • Media
    Media
      • Press releases
      • Calliditas in Media
      • Calliditas Media Kit
      • TARPEYO Media Kit (US audience only)
      • Subscribe
      • Contacts
  • Contact Us
    Contact Us
      • Offices
      • Partnerships and Inquires
      • Investor Relations
      • Media
      • Medical Inquiries
  • Svenska

Financial Reports and Presentations

2019
  • 2022
  • 2021
  • 2020
  • 2018
  • 2017
Presentations
  • Annual Reports
  • Company presentations
  • Interim Reports
  • All types
  Report Presentation Webcast
November 14, 2019 Interim Report Q3 2019
August 15, 2019 Interim Report Q2 2019
May 8, 2019 Interim Report Q1 2019
April 4, 2019 Annual Report 2018
February 7, 2019 Year-end report 2018
  • Investors
    • The Share
      • Trading information
      • Ownership structure
      • Share capital development
      • Dividend policy
      • Analyst coverage
    • Financial Reports and Presentations
    • SEC Filings
    • Press Releases
    • Financial Calendar
    • IR Calendar
    • Subscribe
    • Contacts
    • Investor FAQs

Calliditas Therapeutics AB
D5, Kungsbron 1
SE-111 22 Stockholm
Sweden

Company number: 556659-9766

  • Privacy policy
  • About cookies

© Calliditas Therapeutics AB 2022